Y-Intercept (HK)’s Standard BioTools LAB Stock Holding History

Y-Intercept (HK)’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Buy	+263,273	New	+$249K	﹤0.01%	1554
2024 Q2	–	Sell	-110,882	Closed	-$300K	–	1662
2024 Q1	$300K	Buy	110,882 +71,374	+181%	+$172K	0.02%	952
2023 Q4	$87.3K	Buy	+39,508	New	+$84.3K	0.01%	1113
2023 Q2	–	Sell	-31,647	Closed	-$61.7K	–	1520
2023 Q1	$61.7K	Buy	+31,647	New	+$62.5K	0.01%	1098
2022 Q3	–	Sell	-13,132	Closed	-$21K	–	1133
2022 Q2	$21K	Buy	+13,132	New	+$32.5K	﹤0.01%	787

Other funds holding LAB

MAM

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Y-Intercept (HK)'s LAB Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Standard BioTools (LAB) in Q2 2026: 263,273 shares worth $217K. The stake represents ﹤0.01% of the portfolio and ranks #1554 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in LAB as recently as Q1 2024.

Y-Intercept (HK) first reported a position in LAB in Q2 2022 and has held it in 5 quarters since. The position peaked at $300K in Q1 2024. 5 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Y-Intercept (HK) held 263,273 shares of Standard BioTools worth $217K as of Q2 2026.
Standard BioTools was a new Y-Intercept (HK) position in Q2 2026.
Standard BioTools made up ﹤0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1554 holding.
Y-Intercept (HK) first reported a position in Standard BioTools in Q2 2022 and has held it in 5 quarters since.
Y-Intercept (HK)'s Standard BioTools position peaked at $300K in Q1 2024.
5 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.